Cost attributable to nosocomial bacteremia. Analysis according to microorganism and antimicrobial sensitivity in a university hospital in Barcelona

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Riu, Marta ^a,b   Chiarello, Pietro ^a,b   Terradas, Roser ^a,b   Sala, Maria ^a,c   Garcia Alzorriz, Enric ^a   Castells, Xavier ^a,c   Grau, Santiago ^a,b   Cots, Francesc ^a  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Unidad Docente Multiprofesional de Atención Familiar y Comunitaria Oeste   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; CLOXACILLIN; COLISTIN; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; METICILLIN; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; CONTROLLED STUDY; COST OF ILLNESS; ESCHERICHIA COLI INFECTION; FEMALE; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PROPENSITY SCORE; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; SPAIN; STAPHYLOCOCCAL BACTEREMIA; UNIVERSITY HOSPITAL; BACTERIUM; COMPARATIVE STUDY; COST; CROSS INFECTION; ECONOMICS; HOSPITALIZATION; MICROBIOLOGY; MIDDLE AGED; TEACHING HOSPITAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BACTEREMIA; BACTERIA; COSTS AND COST ANALYSIS; CROSS INFECTION; FEMALE; HOSPITALIZATION; HOSPITALS, TEACHING; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPAIN;

EID: 84963728557     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153076     Document Type: Article

References (47)

1. Allué N, Chiarello P, Bernal Delgado E, Castells X, Giraldo P, Martínez N, et al. Impacto económico de los eventos adversos en los hospitales españoles a partir del Conjunto Mínimo Básico de Datos. Gac Sanit. 2014; 28(1):48-54.
2. Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clinical Microbiology and Infection. 2013. p. 501-9. doi: 10.1111/1469- 0691.12195 PMID: 23473333.
3. Riu M, Terradas R, Sala M, Comas M, Knobel H, Grau S, et al. Costes asociados a las bacteriemias nosocomiales en un hospital universitario. Enferm Infecc Microbiol Clin. 2012 Mar; 30(3):137-42. doi: 10.1016/j.eimc.2011.11.006 PMID: 22206947.
4. Pirson M, Dramaix M, Struelens M, Riley T V, Leclercq P. Costs associated with hospital-acquired bacteraemia in a Belgian hospital. J Hosp Infect. 2005 Jan; 59(1):33-40. PMID: 15571851.
5. Fukuda H, Lee J, Imanaka Y. Variations in analytical methodology for estimating costs of hospitalacquired infections: a systematic review. J Hosp Infect. Elsevier Ltd; 2011 Feb; 77(2):93-105. doi: 10. 1016/j.jhin.2010.10.006 PMID: 21145131.
6. Fariñas MC, Martínez-Martínez L. Infecciones causadas por bacterias gramnegativas multirresistentes: enterobacterias, Pseudomonas aeruginosa, Acinetobacter baumannii y otros bacilos gramnegativos no fermentadores. Enferm Infecc Microbiol Clin. 2013; 31(6):402-9.
7. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007 Nov; 60(5):913-20. PMID: 17848376.
8. Roberts RR, Hota B, Ahmad I, Scott RD, Foster SD, Abbasi F, et al. Hospital and societal costs of antimicrobial- resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009 Oct 15; 49(8):1175-84. doi: 10.1086/605630 PMID: 19739972.
9. CDC. Antibiotic resistance threats in the United States, 2013 [Internet]. 2013. Available: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.
10. Disease EC for, editor. The bacterial challenge : time to react [Internet]. ECDC/EMEA. The bacterial challenge: time to react. Stockholm; 2009. Available: http://www.ecdc.europa.eu/en/publications/Publications/0909-TER-The-Bacterial-Challenge-Time-to-React.pdf.
11. Roberts RR, Scott RD, Hota B, Kampe LM, Abbasi F, Schabowski S, et al. Costs attributable to healthcare- acquired infection in hospitalized adults and a comparison of economic methods. Med Care. 2010; 48(11):1026-35. doi: 10.1097/MLR.0b013e3181ef60a2 PMID: 20940650.
12. Kilgore M, Brossette S. Cost of bloodstream infections. Am J Infect Control. 2008 Dec; 36(10):S172. e1-3.
13. Graves N, Weinhold D, Tong E, Birrell F, Doidge S, Ramritu P, et al. Effect of healthcare-acquired infection on length of hospital stay and cost. Infect Control Hosp Epidemiol. 2007 Mar; 28(3):280-92. PMID: 17326018.
14. Riu M, Chiarello P, Terradas R, Sala M, Castells X, Knobel H, et al. [Economic impact of nosocomial bacteraemia. A comparison of three calculation methods]. Enferm Infecc Microbiol Clin. 2015;(xx: ):5- 10.
15. Beyersmann J, Kneib T, Schumacher M, Gastmeier P. Nosocomial infection, length of stay, and timedependent bias. Infect Control Hosp Epidemiol. 2009; 30(3):273-6. doi: 10.1086/596020 PMID: 19193018.
16. Cots F, Chiarello P, García-alzórriz E, Peláez E, Castells X. Cost de l'activitat assistencial. Variable de resultat per a la gestió clínica [Internet]. Barcelona; 2010. Available: https://www.rechosp.org/mybox/cms/1505.
17. Defez C, Fabbro-Peray P, Cazaban M, Boudemaghe T, Sotto A, Daurès JP. Additional direct medical costs of nosocomial infections: an estimation from a cohort of patients in a French university hospital. J Hosp Infect. 2008 Feb; 68(2):130-6. doi: 10.1016/j.jhin.2007.11.005 PMID: 18201796.
18. Tansarli GS, Karageorgopoulos DE, Kapaskelis A, Falagas ME. Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Rev Anti Infect Ther. 2013 Mar; 11 (3):321-31. doi: 10.1586/eri.13.4 PMID: 23458771.
19. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Stokholm: ECDC; 2012.
20. Larson EL. Factors associated with variation in estimates of the cost of resistant infections. Med Care. 2010; 48(9):767-75. doi: 10.1097/MLR.0b013e3181e358b9 PMID: 20706168.
21. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2010 Jan; 31(1):47-53. doi: 10.1086/649021 PMID: 19951202.
22. Morales E, Cots F, Sala M, Comas M, Belvis F, Riu M, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res; 2012 Jan; 12(1):122.
23. Horan TC, Andrus M, Dudeck M a. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008 Jun; 36(5):309-32. doi: 10.1016/j.ajic.2008.03.002 PMID: 18538699.
24. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012 Mar; 18(3):268-81. doi: 10. 1111/j.1469-0691.2011.03570.x PMID: 21793988.
25. Jensen US, Knudsen JD, Wehberg S, Gregson DB, Laupland KB. Risk factors for recurrence and death after bacteraemia: a population-based study. Clin Microbiol Infect. 2011 Aug; 17(8):1148-54. doi: 10.1111/j.1469-0691.2011.03587.x PMID: 21714830.
26. Cots F, Chiarello P, Carreras M, González JG, Heras D, de Imaña M, Vecina F, del Oro M VN. Red Española de Costes Hospitalarios (RECH): bases para una gestión clínica basada en la evidencia. Gestión y Evaluación Costes Sanit. 2012; 13(3):369-83.
27. Instituto Nacional de Estadística [Internet]. Índice de precios al consumo. Available: http://www.ine.es/jaxi/menu.do?type=pcaxis&path=/t25/p138&file=inebase&L=0.
28. Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, Berger K, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006 Feb 1; 163(3):262-70. PMID: 16371515.
29. Nielsen KL, Pedersen TM, Udekwu KI, Petersen A, Skov RL, Hansen LH, et al. Fitness cost: a bacteriological explanation for the demise of the first international methicillin-resistant Staphylococcus aureus epidemic. J Antimicrob Chemother. 2012 Jun; 67(6):1325-32. doi: 10.1093/jac/dks051 PMID: 22378682.
30. Filice G a, Nyman J a, Lexau C, Lees CH, Bockstedt L a, Como-Sabetti K, et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol. 2010 Apr [cited 2014 Dec 19]; 31(4):365-73. doi: 10.1086/651094 PMID: 20184420.
31. Rubio-Terrés C, Garau J, Grau S, Martinez-Martinez L. Cost of bacteraemia caused by methicillinresistant vs. methicillin-susceptible Staphylococcus aureus in Spain: A retrospective cohort study. Clin Microbiol Infect. 2010; 16:722-8. doi: 10.1111/j.1469-0691.2009.02902.x PMID: 19712112.
32. Park SY, Son JS, Oh IH, Choi JM, Lee MS. Clinical impact of methicillin-resistant Staphylococcus aureus bacteremia based on propensity scores. Infection [Internet]. 2011 Apr [cited 2014 Dec 19]; 39 (2):141-7.
33. Ben-David D, Novikov I, Mermel L a. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin susceptible S. aureus bloodstream infection? Infect Control Hosp Epidemiol. 2009 May; 30(5):453-60. doi: 10.1086/596731 PMID: 19344266.
34. Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Cisneros JM, Peña C, et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol. 2010 May; 48(5):1726-31. doi: 10.1128/JCM.02353-09 PMID: 20181897.
35. Hoenigl M, Wagner J, Raggam RB, Prueller F, Prattes J, Eigl S, et al. Characteristics of hospitalacquired and community-onset blood stream infections, South-East Austria. PLoS One. 2014 Jan; 9(8): e104702. doi: 10.1371/journal.pone.0104702 PMID: 25105287.
36. Ghadiri H, Vaez H, Khosravi S, Soleymani E. The antibiotic resistance profiles of bacterial strains isolated from patients with hospital-acquired bloodstream and urinary tract infections. Crit Care Res Pract. 2012 Jan; 2012:890797. doi: 10.1155/2012/890797 PMID: 23304471.
37. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase- producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol. 2006; 27(11):1226-32. PMID: 17080381.
38. Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of healthcare- and community associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012 Sep; 55(6):807-15. doi: 10.1093/cid/cis552 PMID: 22700828.
39. Harbarth S, Sax H, Gastmeier P. The preventable proportion of nosocomial infections: an overview of published reports. J Hosp Infect. 2003 Aug; 54(4):258-66. PMID: 12919755.
40. Septimus E, Weinstein R a, Perl TM, Goldmann D a, Yokoe DS. Approaches for preventing health care associated infections: go long or go wide? Infect Control Hosp Epidemiol. 2014 Jul; 35(7):797-801. doi: 10.1086/676535 PMID: 24915206.
41. Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006; 355:2725-32. PMID: 17192537.
42. Yilmaz G, Caylan R, Aydin K, Topbas M, Koksal I. Effect of education on the rate of and the understanding of risk factors for intravascular catheter-related infections. Infect Control Hosp Epidemiol. 2007; 28:689-94. PMID: 17520542.
43. Terradas R, Riu M, Segura M, Castells X, Lacambra M, Alvarez JC, et al. Results of a multidisciplinary and multifocal project to reduce bacteraemia caused by central venous catheters in non critical patients in a university hospital. Enferm Infecc Microbiol Clin. 2011; 29(1):14-8. doi: 10.1016/j.eimc.2010.06. 007 PMID: 21194807.
44. Freixas N, Bella F, Limón E, Pujol M, Almirante B, Gudiol F. Impact of a multimodal intervention to reduce bloodstream infections related to vascular catheters in non-ICU wards: A multicentre study. Clin Microbiol Infect. 2013; 19:838-44. doi: 10.1111/1469-0691.12049 PMID: 23130638.
45. Burden AR, Torjman MC, Dy GE, Jaffe JD, Littman JJ, Nawar F, et al. Prevention of central venous catheter-related bloodstream infections: is it time to add simulation training to the prevention bundle? J Clin Anesth. Elsevier Inc.; 2012 Nov; 24(7):555-60. doi: 10.1016/j.jclinane.2012.04.006 PMID: 23101770.
46. Greene LLR. Healthcare-Associated Infections. The regulatory landscape. Infection Control Today. Phoenix; 2013.
47. Carlet J. The World Alliance Against Antibiotic Resistance -WAAAR- declaration against antibiotic resistence [Internet]. 2014. Available: http://www.ac2bmr.fr/index.php/en/waaar-declaration.